Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several
cancers carrying mutations in the breast and ovarian cancer susceptibility genes BRCA1 …

Simple Summary The prognosis for metastatic prostate cancer patients remains poor.
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer and is a …

Background Preliminary trial results showed that enzalutamide significantly improved
metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer …

Purpose: Successful implementation of genomic testing in clinical practice is critical for
identification of men with metastatic castration-resistant prostate cancer (mCRPC) eligible for …

… Michael P. Kolinsky has received personal fees for serving as a consultant for Merck.
Marinela Augustin has received personal fees for serving as a consultant to Bristol Myers Squib, …

… Michael P. Kolinsky has received personal consultancy fees from Astellas, AstraZeneca,
Bayer, BMS, Eisai, Ipsen, Janssen, and Merck. William R. Berry has received personal advisory …

Background Germline DNA damage repair gene mutation (gDDRm) is found in >10% of
metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard …

PURPOSE There is an unmet need for therapeutic options that prolong survival for patients
with heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC). The phase …

Background The availability of multiple new treatments for metastatic castration-resistant
prostate cancer (mCRPC) mandates earlier treatment switches in the absence of a response. A …

Background Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating
tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant …